|
Comparison of the effects of propranolol and norepinephrine on the toxicity of Caco-2 cancer cell lines at three times: 24, 48, and 96 hours
|
Mohammad Naderi1   , Najmeh Hadizadeh Shirazi2  , Zahra Tahmasebi Fard3 |
1- Department of Biology, Science and Research Branch, Science and Research Branch, Islamic Azad University, Tehran, Iran.
2- Department of Biology, Roudehen Branch, Islamic Azad of university, Roudehen, Iran , Na.hadizade@iau.ac.ir
3- Department of Biology, Roudehen Branch, Islamic Azad of university, Roudehen, Iran |
|
|
Abstract: (483 Views) |
Background: Colorectal cancer is among the most common cancers in developed and developing societies. Studies have shown that lifestyle and especially stress can be effective in getting this condition. Considering the key role of norepinephrine in the occurrence of stress and the frequency of use of stress-suppressing drugs such as propranolol, this research aimed to investigate the cytotoxicity of norepinephrine and propranolol on colorectal cell lines by the MTT assay method.
Materials and methods: The Caco-2 cell line was purchased from the cell bank of the Pasteur Institute Research Center of Iran. After cell culture, it was treated with serial concentrations (0-100μg/mL) of propranolol and norepinephrine for 24, 48, and 96 hours, and the toxicity of the treatments was evaluated with the MTT assay test, compared to the control group.
Results: After 24 hours of cell culture with the treatments, there was no significant change in the growth rate of the cells. After 48 hours, only propranolol at a concentration of 30.11 μg/mL could lead to 50% mortality. After 96 hours, propranolol with a concentration of 3.42 μg/mL and norepinephrine with a concentration of 91.1 μg/mL showed 50% growth inhibition.
Conclusion: According to the data obtained from the research, it seems that although both additives had a toxic effect on the cells, propranolol had more toxicity on Caco-2 colorectal cancer cells than norepinephrine. Further studies are suggested in the field of new clinical applications for propranolol.
|
|
| Keywords: Colorectal cancer cell line Caco-2, Norepinephrine, Propranolol, MTT assay. |
|
|
Full-Text [PDF 958 kb]
(145 Downloads)
|
Semi-pilot: Basic |
Subject:
Molecular Biology
Received: 2024/01/19 | Accepted: 2024/04/7 | Published: 2024/11/30
|
|
|
|
|
|
|
| References |
1. Faroughi F, Fathnezhad-Kazemi A, Sarbakhsh P. Factors affecting quality of life in women with breast cancer: a path analysis. BMC Womens Health 2023;23:578. [ DOI:10.1186/s12905-023-02755-9] 2. Alzahrani SM, Al Doghaither HA, Al-Ghafari AB. General insight into cancer: An overview of colorectal cancer (Review). Mol Clin Oncol 2021;15:271. [ DOI:10.3892/mco.2021.2433] 3. Faulkner S, Jobling P, March B, Jiang CC, Hondermarck H. Tumor Neurobiology and the War of Nerves in Cancer. Cancer Discov 2019;9:702-710. [ DOI:10.1158/2159-8290.CD-18-1398] 4. Ceyhan GO, Liebl F, Maak M, Schuster T, Becker K, Langer R, et al. The severity of neural invasion is a crucial prognostic factor in rectal cancer independent of neoadjuvant radiochemotherapy. Ann Surg 2010;252:797-804. [ DOI:10.1097/SLA.0b013e3181fcab8d] 5. Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 2012;18:1201-6. [ DOI:10.1158/1078-0432.CCR-11-0641] 6. Sharkawi FZ, Shemy HA, Khaled H. Anticancer activity of some commercial antihypertensive drugs by Neutral Red assay. Life Sci J 2013;10:609-613. 7. Thaker PH, Lutgendorf SK, Sood AK. The neuroendocrine impact of chronic stress on cancer. Cell cycle 2007;6:430-3. DOI: 10.4161/cc.6.4.3829 [ DOI:10.4161/cc.6.4.3829] 8. Barron TI, Sharp L, Visvanathan K. Beta-adrenergic blocking drugs in breast cancer: a perspective review. Ther Adv Med Oncol 2012;4:113-25. [ DOI:10.1177/1758834012439738] 9. Guo K, Ma Q, Wang L, Hu H, Li J, Zhang D. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep 2009;22:825-30. [ DOI:10.3892/or_00000505] 10. Pimentel MA, Chai MG, Le CP, Cole SW, Sloan EK, Eds. Sympathetic nervous system regulation of metastasis. Madame Curie Bioscience Database: Landes Bioscience; 2013. 11. Caparica R, Bruzzone M, Agostinetto E, De Angelis C, Fêde Â, Ceppi M, de Azambuja E. Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis. ESMO Open 2021;6:100066. [ DOI:10.1016/j.esmoop.2021.100066] 12. Al-Majed AA, Bakheit AHH, Abdel Aziz HA, Alajmi FM, AlRabiah H. Propranolol. Profiles Drug Subst Excip Relat Methodol 2017;42:287-338. [ DOI:10.1016/bs.podrm.2017.02.006] 13. Verhoeckx K, Cotter P, López-Expósito I, Kleiveland C, Lea T, Mackie A, Requena T, Swiatecka D, Wichers H, Eds. The Impact of Food Bioactives on Health: in vitro and ex vivo models [Internet]. Cham (CH): Springer; 2015. [ DOI:10.1007/978-3-319-16104-4] 14. Wang F, Liu H, Wang F, Xu R, Wang P, Tang F, et al. Propranolol suppresses the proliferation and induces the apoptosis of liver cancer cells. Mol Med Rep 2018;17:5213-5221. [ DOI:10.3892/mmr.2018.8476] 15. Masur K, Niggemann B, Zanker KS, Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 2001;61:2866-9. 16. Hu Q, Liao P, Li W, Hu J, Chen C, Zhang Y. Clinical use of propranolol reduces biomarkers of proliferation in gastric cancer. Front Oncol 2021;11:613-628. [ DOI:10.3389/fonc.2021.628613] 17. Brohée L, Demine S, Willems J, Arnould T, Colige AC, Deroanne CF. Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment. Oncotarget 2011;1126:1-15. 18. Lutgendorf SK, Sood AK, Antoni MH. Host factors and cancer progression: biobehavioral signaling pathways and interventions. J Clin Oncol 2010;28:4094-4098. [ DOI:10.1200/JCO.2009.26.9357] 19. Acevedo Santiago A, Cruz Robles M, Monteiro AN, Armaiz Pena GN. Characterizing the Contribution of Adrenergic Signaling to Olaparib Resistance in Ovarian Cancer Cells. The FASEB J 2022;S1:36-41. [ DOI:10.1096/fasebj.2022.36.S1.R2127] 20. Giampieri, R. Cantini, L. Giglio, E. Bittoni, A. Lanese, A. Crocetti, S. et al. Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing. Cancers 2020;12:2724. [ DOI:10.3390/cancers12102724] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Naderi M, Hadizadeh Shirazi N, Tahmasebi Fard Z. Comparison of the effects of propranolol and norepinephrine on the toxicity of Caco-2 cancer cell lines at three times: 24, 48, and 96 hours. MEDICAL SCIENCES 2024; 34 (4) :394-400 URL: http://tmuj.iautmu.ac.ir/article-1-2209-en.html
|
